In an attempt to develop a lead for the application of 2-5A-antisense to the targeted destruction of human immunodeficiency virus (HIV) RNA, specific target sequences within the HIV mRNAs were identified by analysis of the theoretical secondary structure. 2-5A-antisense chimeras were chosen against a total of 11 different sequences: three in the gag mRNA, three in the rev mRNA and five in the tat mRNA. 2-5A-antisense chimera synthesis was accomplished using solid-phase phosphoramidite chemistry. These chimeras were evaluated for their activity in a cell-free assay system using purified recombinant human RNase L to effect cleavage of 32 P-labelled RNA transcripts of plasmids derived from HIV NL4-3. This screening revealed that of the three 2-5A-antisense chimeras targeted against gag mRNA, only one had significant HIV RNA cleavage activity, approximately 10-fold-reduced compared to the parent 2-5A tetramer and comparable to that reported for the prototypical 2-5A-anti-PKR chimera, targeted against PKR mRNA. The cleavage activity of this chimera was specific, since a scrambled antisense domain chimera and a chimera without the key 5′monophosphate moiety were both inactive. The 10 other 2-5A-antisense chimeras against tat and rev had significantly less activity. These results imply that HIV gag RNA, like PKR RNA and a model HIV tat-oligoA-vif RNA, can be cleaved using the 2-5A-antisense approach. The results further imply that not all regions of a potential RNA target are accessible to the 2-5A-antisense approach.
Since the early reports on the inhibition of virus replication by antisense DNA, a number of different mechanistic and structural modifications have been developed to target human immunodeficiency virus (HIV) with this new therapeutic principle. The modifications used may be broadly characterized as those consisting of DNA oligomers with modified or unmodified internucleotide linkages, of which phosphorothioates (Matsukura et al., 1987; Kin et al., 1991; Zhang et al., 1995) and methylphosphonates (Sarin et al., 1988) are most widely known. Several reports have detailed studies of HIVtargeted oligonucleotides containing modified bases (Lund et al., 1995) , 2′-O-methyl RNA oligomers (Shibahara et al., 1989) , oligomers with intercalators at the 3′ terminus (Mori et al., 1989) and oligomers with an α configuration (Rayner et al., 1989) . Ribozymes (Homann et al., 1993) and antisense RNA (Sczakiel et al., 1990; Cagnon et al., 1995) have also been examined for their activity against HIV.
The 2-5A-antisense strategy also provides a potential approach to the control of HIV gene expression. Covalent conjugation of 5′-phosphorylated-2′,5′-oligoadenylate (2-5A) to a 3′,5′-deoxynucleotide of a complementary sequence to a targeted sequence in an RNA provides a novel reagent which effects the selective and specific cleavage of RNA both in cell-free systems and in intact cells Maitra et al., 1995; Cirino et al., 1997) . This strategy relies on the chimeric nucleic acid-induced recruitment to a chosen RNA and the subsequent activation of RNase L, which then cleaves the targeted RNA, thus providing a new approach for the targeted ablation of an mRNA and the protein which it specifies. Antiviral Chemistry & Chemotherapy 9: [225] [226] [227] [228] [229] [230] [231] Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense Introduction ©1998 International Medical Press 0956-3202/98/$17.00
Materials and Methods
Oligonucleotide synthesis 2-5A-antisense chimeras were synthesized automatically on an ABI (Foster City, Calif., USA) 392 DNA/RNA synthesizer using multiple cycles with phosphoramidite chemistry and previously described techniques (Xiao et al., 1996) . The four different domains present within 2-5Aantisense oligonucleotides, each of which requires different coupling waiting times, were: antisense DNA, 1,4-butanediol linker, 2′,5′-oligoadenylate and 5′-monophosphate. The corresponding coupling waiting times were: 15, 300, 600 and 60 s, respectively. Phosphoramidites were purchased from ABI. Phosphorylation was performed with 2-[2-(4,4′-dimethoxytrityl)ethylsulphonyl]ethyl-2-cyanoethyl)-N,N-diisopropyl)phosphoramidite (Glen Research, Sterling, Va., USA).
Oligonucleotide purification
For HPLC purification, a Beckman System Gold controlling an IBM PS/2 computer, two 110B solvent delivery modules and a 167 UV/Vis variable wavelength detector were used. The ion-pair method utilized a Hamilton polystyrene reverse phase (PRP-1) 300×7 mm column with a flow rate of 1.5 ml/min running a convex gradient of 5-90% mobile phase B in A during 60 min, where A was 10 mM tetrabutyl ammonium phosphate (TBAP) solution pH 7.5 and B was 10 mM TBAP pH 7.5 in acetonitrile : water (8 : 2, v/v) solution. Oligonucleotide preparations were desalted with C-18 Sep-Pak cartridges.
Oligonucleotide characterization
2-5A-antisense chimeras were analysed by digestion with snake venom phosphodiesterase followed by HPLC analysis of the products (Fig. 1a ). For HPLC analysis, a HP1050 instrument with Chemstation software and data analysis was used throughout. The enzymic degradation analytical method used a Beckman Ultrasphere ODS (4.6×250 mm) column with a flow rate of 0.5 ml/min (a) Snake venom phosphodiesterase digestion of 3. The identity of the nucleotide product and its relative integration is indicated above each HPLC peak. (b) Capillary electrophoresis of 3. Performed on a ABI 270A-HT capillary electrophoresis instrument using MICRO-GEL 100 gel-filled capillaries (50 mM i.d., effective length 27 cm) with running buffer, 75 mM Tris-phosphate pH 7.6 in H 2 O : MeOH (90 : 10, v/v). Detection was at 260 nm. A typical chimera electropherogram was obtained using a sample concentration of 0.06 A 260 /ml, electrokinetic injection was 2 s at -5 kV. Current was -14 µA (17 µA) and the operation temperature was 30°C. In many instances, the sample was analysed in a coinjection with a standard reference dodecamer oligodeoxyribonucleotide. running 2% B isocratically for 20 min, then a linear gradient of 2-45% B in A during 15 min, followed by isocratic conditions for another 10 min where A was 100 mM ammonium phosphate pH 5.5 and B was methanol : water (1:1, v/v). As seen in Fig. 1 , the identity and relative ratios of nucleotidic products confirmed the composition predicted from the solid support synthesis procedure.
2-5A-antisense chimeras also were analysed by capillary gel electrophoresis ( Fig. 1b ). Conditions for capillary gel electrophoresis have been described previously (Xiao et al., 1996) . An authentic marker 12-mer, d(AGCT) 3 , was included as a reference.
The nucleotide sequence of 3 was confirmed by Maxam-Gilbert sequencing (Fig. 2) . The specific conditions for analysis of 2-5A-antisense chimeras using Maxam-Gilbert sequencing have been described elsewhere (Xiao et al., 1996) .
Cleavage of HIV RNA in vitro
In vitro synthesis and purification of RNA and labelling for cleavage assays. HIV-1 gag, tat and rev RNA were synthesized from pSP5 and pSP7 plasmids (a gift from Klaus Strebel, NIH, Bethesda, Md., USA) containing the respective cDNAs. A truncated form of gag RNA (982 nucleotides) was synthesized from pSP5 plasmids after linearizing with PstI and was transcribed in vitro using SP6 RNA polymerase (Life Technologies). HIV-1 tat and rev RNA were transcribed using SP6 RNA polymerase from pSP7 plasmids after linearization with SspI. This transcript was 411 nucleotides long and contained the sequences of the first exons of both tat and rev.
Approximately 100-200 µg of RNA transcripts were labelled at the 5′ terminus using [γ-32 P]ATP. The respective RNAs were treated first with alkaline phosphatase to remove 5′-phosphate groups before 5′-end labelling. This was performed by incubating 15-16 µg RNA for 30 min at 37°C with 1.5 units of calf intestinal phosphatase (Boehringer Mannheim) and the buffer supplied by the manufacturer. After incubation with proteinase K to digest alkaline phosphatase and phenol : chloroform : isoamyl alcohol, the RNA was precipitated with ethanol, washed with 70% ethanol and dissolved in RNase-free water. RNA was then labelled with T4 polynucleotide kinase (2 U; USB) and 50 µCi of [γ-32 P]ATP (3000 Ci/mmol). After repeated phenol : chloroform : isoamyl alcohol deproteinization, the RNA was passed through a Sephadex G-50 column to remove free nucleotides and then ethanolprecipitated. The full-length transcripts were dissolved in H 2 O and then diluted with an equal volume of gel sample buffer (deionized 80% formamide containing 10 mM EDTA pH 8.0, 1.0 mg/ml xylene cyanol and 1.0 mg/ml bromophenol blue). Electrophoresis was on a 5% polyacrylamide-8 M urea gel in TBE (90 mM Tris-borate pH 7.5, 2 mM EDTA pH 8.0) at 300 V for 1 h.
After exposure of the gel to Kodak X-OMAT film for 5-15 min, the portion of the gel corresponding to fulllength product was excised with a sterile razor blade, minced and incubated overnight with 400 µl of buffer (0.5 M ammonium acetate pH 5.2, 1.0 mM magnesium acetate and 1.0% SDS) to elute the RNA.
RNA cleavage with recombinant RNase L. The respective 2-5A antisense chimeras were mixed with the purified 5′end labelled mRNAs, in a buffer containing 25 mM Tris-HCl pH 7.4, 10 mM magnesium acetate, 8 mM 2mercaptoethanol and 100 mM KCl at 0°C. After 5-10 min, 25 ng of recombinant RNase L, produced in SF21 cells from a baculovirus vector and purified to homogeneity by fast protein liquid chromatography, was added to a final volume of 20 µl. The 2-5A or 2-5A-antisense chimera was added to the reaction mixture to give, depending upon the experiment, a range of final concentrations from 0.1-1000 nM. Incubations were carried out at 37°C for 30 min. Reactions were terminated by adding gel sample buffer (USB). Cleavage of 32 P-labelled RNAs (50-200 nM) was monitored according to the published procedure Maitra et al., 1995) by electrophoresis in 7% polyacrylamde-8 M urea gel, autoradiography and analysis in a Phosphorimager (Molecular Dynamics). Gag RNA cleavage experiments were performed in triplicate and tat and rev RNA cleavage experiments were performed in duplicate.
Results
Design and preparation of 2-5A-antisense chimeras: selection of HIV RNA targets
Based on earlier results with various types of antisense oligonucleotides (De Clercq, 1995a,b) we have concentrated on HIV gag, rev and tat RNAs as the targets most likely to afford in vitro inhibition of HIV replication. A number of regions within gag mRNA have been reported to be good targets; for instance, Lisziewicz et al. (1993) provided evidence that certain antisense oligonucleotides may target certain gag mRNAs in a dose-dependent sequence-specific manner. However, because of amplification of structural proteins, RNAs coding for proteins needed for early regulatory functions such as tat and rev may be preferred over structural proteins (Lisziewicz et al., 1992; Kinchington et al., 1992) . In addition, these latter proteins are present in lesser abundance than the gag gene product. An analysis of the theoretical secondary structure of appropriate regions of HIV RNA was carried out using the algorithm developed by Zuker (1989) . This theoretical analysis guided the design of a series of 2-5A-antisense chimeras directed against a variety of specific sequences in the HIV RNA. Based on their potential availability for hybridization with a complementary antisense sequence, a total of 11 different HIV RNA sequences were selected: three in the gag RNA, three in the rev RNA and five in the tat RNA. Sequence numbering was with respect to the HIV-1 NY5/BRU (LAV-1) recombinant clone pNL4-3 (Genbank accession number M192210). Table 1 lists the 2-5A-antisense chimeras synthesized and their corresponding RNA target sequence locations. Unmodified phosphodiester-based chimeric oligonucleotides were generated in this study since the goal was to discover sensitive HIV RNA targets using a cell-free system and purified human recombinant RNase L wherein issues of oligonucleotide stability were of minimal concern. Promising leads found through this screening could then be the basis of future chemical modifications to enhance stability for cellular application.
Chemistry 2-5A-antisense chimeras (Table 1) were synthesized against each of 11 sequences using modifications of the previously reported methodology Xiao et al., 1996) and purification by a Hamilton PRP HPLC column and dialysis. The general structure of these chimeric oliognucleotides was: pA2′p(5′A2′p) 2 5′A2′pBupBup5′dN3′[p5′dN3′] n p5′dN.
The assigned structure of each chimera was corroborated by quantitative HPLC analysis of snake venom phosphodiesterase digests. This analysis assessed the ratio of all component deoxyribonucleotides, the AMP-butanediol moiety, and the 5′-AMP from 2-5A (Xiao et al., 1996) . This latter nucleotide also permitted corroboration of the completeness of 5′-phosphorylation, an absolute requirement for optimum activation of the RNase L. Each oligonucleotide in Table 1 gave a snake venom phosphodiesterase digestion HPLC analysis pattern that confirmed the identity (retention time) and ratio (integrated peak intensity) with the assigned structure based on the oligonucleotide synthesizer programming. For illustration, the digestion result for chimera 3, of ≥90% purity (Fig. 1b) is shown in Fig. 1a . The exact sequence of the antisense domain was confirmed using Maxam-Gilbert sequencing. The result of such a sequencing of chimera 3 is shown in Fig. 2 .
Binding assays
The RNase L-binding ability of three chimeras, targeted against gag, was examined in a radiobinding assay (Table 2) (Silverman & Krause, 1987) . This assay evaluated the ability of the chimera to displace the labelled probe pA2′p(5′A2′p) 2 5′A3′[ 32 P]p5′C3′p from RNase L. Chimeras 1-3 all gave an IC 50 (concentration required to inhibit probe binding by 50%) of approximately 1.5×10 -8 M, not significantly different from the IC 50 of 2.2×10 -8 M obtained with parent p5′A2′(p5′A2′)2′p5′A itself (Table 2 ). In a separate experiment (Table 2) , when the chimeras 3-5 were evaluated similarly, 5, the scrambled oligonucleotide control chimera for 3, bound equally as well as 3. However, the non-phosphorylated core chimera, 4, bound with well over 2 log 10 lower affinity, with an IC 50 of 3×10 -6 M.
In vitro cleavage assays of HIV-1 gag RNA by 2-5A-antisense chimeras 1-5
The RNA cleavage ability of each of the 2-5A-antisense chimeras was ascertained in an in vitro assay that employed purified recombinant RNase L and 32 P-labelled gag RNA (982 nucleotides). Of the three 2-5A antisense chimeras synthesized, only one (3) (nucleotides 917-935) resulted in a 95% cleavage of the target gag RNA substrate at a concentration of 100 nM. The other two antisense chimeras (1 and 2, nucleotides 790-808 and 850-868) had no effect at 100 or 200 nM under the same experimental conditions ( Fig. 1) ( Table 3) . The selectivity and specificity of 3 was investigated with a set of control chimeras (Table 3) . First, a mismatched 2− 5A-antisense chimera (5), which lacked sequence specificity, was found not to cleave at 200 nM. Second, a non-phosphorylated 'core' trimer chimera (4), which would not be able to activate RNase L , did not cleave the HIV RNA at 200 nM. Chimera 3 also did not cleave a bcr-abl 5′ transcript, a non-targeted RNA, at a concentration of 200 nM (data not shown).
In vitro cleavage of HIV-1 tat and rev RNAs by chimeras 6-13.
To determine the ability of 2-5A anti-tat and -rev chimeras to cause specific cleavage, an RNA target was constructed containing the overlapping open reading sequences of both tat and rev. The experimental target was synthesized from a pSP64 plasmid containing tat and rev coding sequences and labelled at the 5′ terminus using T4 polynucleotide kinase and purified from a polyacrylamide gel prior to cleavage assay. One of the five synthetic anti-tat chimeras (13) showed 20% and 45% cleavage at 50 and 100 nM oligonucleotide concentration, respectively (data not shown). Discrete products arose from this cleavage (data not shown). 2-5A-Antisense chimeras against other target sequences within tat and rev showed no significant cleavage of target RNA.
Discussion
This screening revealed that of the three 2-5A-antisense chimeras targeted against gag mRNA, only one construct (3) had significant HIV RNA cleavage activity, approximately 10-fold-reduced compared to parent 2-5A tetramer itself and comparable to that reported for the prototypical 2-5Aanti-PKR chimera, targeted against PKR mRNA Maitra et al., 1995) . The cleavage activity of 3 was specific, since a scrambled antisense domain chimera and a chimera without the key 5′-monophosphate moiety were both inactive. The observations that 10 other 2-5A-antisense chimeras against tat and rev had significantly less activity could most probably be related to HIV RNA substrate nucelotide sequence and/or secondary structure, insofar as antisense domain sequence changes did not have a significant effect on binding interac-Targeting RNase L to HIV RNA with 2-5A tions with RNase L itself (Table 1) . The reduced activity of 2-5A-DNA chimeras in comparison to parent 2-5A itself has been described previously (Maitra et al., 1995) . Thus, chimeras without a complementary antisense sequence to a specific RNA are at least 1000-fold less active as RNase L activators than 2-5A itself (Maitra et al., 1995) . When, however, the DNA domain of the chimera is antisense to the RNA target, the resulting 2-5A-antisense chimera is greatly potentiated compared to the chimera with a non-complementary DNA sequence, possibly as a result of creation of a new high-affinity RNA binding site and a proximity effect ( Jencks, 1969) on catalysis (Maitra et al., 1995) . The reduced activity of chimera 3 when compared to 2-5A tetramer is presently not understood, but may relate to the length of the DNA oligonucleotide joined to the 2′,5′-oligoriboadenylate (MR Player & PF Torrence, unpublished observations). These findings imply that (i) 2-5A-antisense chimeras can be employed to target HIV gag RNA for catalytic degradation by RNase L; and (ii) that RNA nucleotide sequences may vary considerably in their sensitivity to the 2-5A-antisense approach. It was not clear what the primary determinants may be for prediction of the susceptibility of a particular RNA sequence to 2-5A-dependent cleavage. It was possible that the selected antisense sequences failed to find and bind to their selected target complementary sequences, in spite of the theoretical predictions of the secondary structure program. Determination of RNA secondary structure as an aid in the design of efficacious antisense oligonucleotides can be approached in several ways, including thermodynamic stability, phylogenetic comparison, chemical and enzymatic probing, and NMR (Chastin & Tinoco, 1993) . The difficulties associated with these and other approaches have been reviewed (Chastin & Tinoco, 1993; Ecker, 1993; Freier, 1993; Milligan et al., 1993) . For instance, tertiary structure complexation can occlude theoretically available binding sites. Thus, selection of an efficiacous antisense oligonucleotide remains largely an empirical effort (Milligan et al., 1993) . In contrast to the passive hybridization ('steric blocking') (Boiziau et al., 1988) and RNase H cleavage mechanisms (Dash et al., 1987) of classical antisense action, 2-5A-antisense-mediated RNase L cleavage may occur outside the region of antisense hybridization (Maitra et al., 1995) . Thus, non-target nucleotide sequences or associated higher-order structures may play a role in dictating post-hybridization cleavage. This may imply the potential for greater selectivity of mRNA degradation with 2-5A-antisense chimeras.
The possible application of 2-5A-antisense to the therapy of virus infections such as HIV will require an increased understanding of the factors that control RNase L activation by such relatively foreign activators represented by chimera 3, and considerably more information on how 2-5A-antisense, as distinct from antisense oligonucleotides per se, may be targeted to sensitive RNA sequences. In addition, the considerable problems of oligonucleotide metabolic stability and delivery will have to be addressed with 2-5A-antisense in common with the general antisense field . The potential of 2-5A-antisense with an increased biological half-life is illustrated by doubly modified chimeras Li et al., 1997) that possess significant antiviral activity against respiratory syncytial virus (Cirino et al., 1997) .
